Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance.
Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.
How Are Biotech ETFs Reacting to Q3 Earnings Releases?
by Sanghamitra Saha
Biotech earnings have come in upbeat in the third quarter.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down.
Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter.
Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.
Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up
by Zacks Equity Research
Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
by Zacks Equity Research
TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook
by Zacks Equity Research
Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
by Zacks Equity Research
Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.
Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates.
Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for LVHD
Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.
Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View
by Zacks Equity Research
Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year. The stock falls in pre-market trading.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 31.94% and 15.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights The Home Depot, Elevance Health, BP, Gilead Sciences and ServiceNow
by Zacks Equity Research
The Home Depot, Elevance Health, BP, Gilead Sciences and ServiceNow are part of the Zacks top Analyst Blog.
Will Gilead Sciences Stock Climb After Q3 Earnings?
by Shaun Pruitt
Big Pharma will close out this week's earnings reports, with Gilead Sciences (GILD) set to give its Q3 results on October 27. With GILD edging towards its 52-week highs, investors will want to see if earnings can support a continued rally in its stock.
Top Stock Reports for The Home Depot, Elevance Health & BP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Elevance Health Inc. (ELV) and BP p.l.c. (BP).